Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent ActivityPRNewsWire • 11/04/21
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2021 and Provide Corporate UpdatePRNewsWire • 11/01/21
Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative ColitisPRNewsWire • 10/28/21
Immunic, Inc. Announces First Psoriasis Patient Enrolled in Ongoing Phase 1 Trial of IMU-935PRNewsWire • 10/27/21
Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple SclerosisPRNewsWire • 09/30/21
Immunic, University Medical Center Goettingen Ink Licensing Pact For Combination Viral Infection TreatmentsBenzinga • 09/22/21
Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19PRNewsWire • 09/22/21
Immunic, Inc. to Participate in Investor and Scientific Conferences in SeptemberPRNewsWire • 09/08/21
Immunic, Inc. Reports Second Quarter 2021 Financial Results and Highlights Recent ActivityPRNewsWire • 08/06/21
Immunic Stock Is Trading Lower After Equity Raise Of $45M To Fund Lead Pipeline CandidatesBenzinga • 07/15/21
Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class RORγt Inverse AgonistPRNewsWire • 07/12/21
Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple SclerosisPRNewsWire • 07/01/21
Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in JulyPRNewsWire • 06/28/21
